Continuous monitoring of circadian variations in intraocular pressure by telemetry system throughout a 12-week treatment with timolol maleate in rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 6, 2005, Pages 436-444

  Akaishi, Takahiro ^a   Ishida, Naruhiro ^a   Shimazaki, Atsushi ^a   Hara, Hideaki ^b   Kuwayama, Yasuaki ^c  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^c OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENOXIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DICLOFENAC; INDOMETACIN; KETAMINE; OFLOXACIN; OXYBUPROCAINE; SODIUM CHLORIDE; TIMOLOL MALEATE; XYLAZINE;

ANIMAL EXPERIMENT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; GLAUCOMA; INTRAOCULAR PRESSURE; LIGHT DARK CYCLE; LONG TERM CARE; MALE; NONHUMAN; RABBIT; TELEMETRY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CIRCADIAN RHYTHM; INSTILLATION, DRUG; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; RABBITS; TELEMETRY; TIME FACTORS; TIMOLOL;

EID: 30544439250     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.436     Document Type: Article

References (31)

1. Anderson, D.R. Glaucoma: The damage caused by pressure. XLVI Edward Jackson memorial lecture. Am. J. Ophthalmol. 108:485-495, 1989.
2. The AGIS Investigators. The advanced glaucoma intervension study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
3. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 126:498-505, 1998.
4. Wilensky, J.T. Diurnal variations in intraocular pressure. Trans. Am. Ophthalmol. Soc. 89:757-790, 1991.
5. Liu, J.H. Circadian rhythm of intraocular pressure. J. Glaucoma 7:141-147, 1998.
6. Liu, J.H. Diurnal measurement of intraocular pressure. J. Glaucoma 10(Suppl 1):S39-S41, 2001.
7. Wilensky, J.T., Gieser, D.K., Mori, M.T., et al. Self-tonometry to manage patients with glaucoma and apparently controlled intraocular pressure. Arch. Ophthalmol. 105:1072-1075, 1987.
8. Asrani, S., Zeimer, R., Wilensky, J., et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma 9:134-142, 2000.
9. Vogel, R., Crick, R.P., Mills, K.B., et al. Effect of timolol versus pilocarpine on visual field progression in patients with primary open-angle glaucoma. Ophthalmology 99:1505-1511, 1992.
10. Schwartz, B., Takamoto, T., Lavin P., et al. Increase of retinal nerve fiber layer thickness in ocular hypertensives with timolol therapy. Acta. Ophthalmol. Scand. 215(Suppl):S22-S32, 1995.
11. Konstas, A.G., Maltezos, A.C., Gandi, S., et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 128:15-20, 1999.
12. Orzalesi, N., Rossetti, L., Invernizzi, T., et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest. Ophthalmol. Vis. Sci. 41:2566-2573, 2000.
13. Krag, S., Andersen, H.B., and Sorensen, T. Circadian intraocular pressure variation with beta-blockers. Acta. Ophthalmol. Scand. 77:500-503, 1999.
14. Sihota, R., Saxena, R., Agarwal, H.C., et al. Peak pressures: Crossover study of timolol and latanoprost. Eur. J. Ophthalmol. 13:546-552, 2003.
15. Akaishi, T., Shimazaki, A., Matsugi, T., et al. Effects of ocular hypotensive agents on the circadian rhythm in intraocular pressure in rabbits as measured by telemetry. Nippon Ganka Gakkai Zasshi 107:513-518, 2003.
16. Schnell, C.R., Debon, C., and Percicot, C.L. Measurement of intraocular pressure by telemetry in conscious, unrestrained rabbits. Invest. Ophthalmol. Vis. Sci. 37:958-965, 1996.
17. McLaren, J.W., Brubaker, R.F., and FitzSimon, J.S. Continuous measurement of intraocular pressure in rabbits by telemetry. Invest. Ophthalmol. Vis. Sci. 37:966-975, 1996.
18. Percicot, C.L., Schnell, C.R., Debon, C., et al. Continuous intraocular pressure measurement by telemetry in alpha-chymotrypsin-induced glaucoma model in the rabbit: Effects of timolol, dorzolamide, and epinephrine. J. Pharmacol. Toxicol. Meth. 36:223-228, 1996.
19. Gregory, D.S. Timolol reduces IOP in normal NZW rabbits during the dark only. Invest. Ophthalmol. Vis. Sci. 31:715-721, 1990.
20. Dinslage, S., McLaren, J., and Brubaker, R. Intraocular pressure in rabbits by telemetry 11: Effects of animal handling and drugs. Invest. Ophthalmol. Vis. Sci. 39:2485-2489, 1998.
21. Liu, J.H.K., and Dacus, A.C. Endogenous hormonal changes and circadian elevation of intraocular pressure. Invest. Ophthalmol. Vis. Sci. 32:496-500, 1991.
22. Yoshitomi, T., Horio, B., and Gregory, D.S. Changes in aqueous norepinephrine and cyclic adenosine monophosphate during the circadian cycle in rabbits. Invest. Ophthalmol. Vis. Sci. 32:1609-1613, 1991.
23. Gallar, J., and Liu, J.H. Stimulation of the cervical sympathetic nerves increases intraocular pressure. Invest. Ophthalmol. Vis. Sci. 34:596-605, 1993.
24. Green, K., Elijah, D., and Lollis, G. Drug effects on aqueous humor formation and pseudofacility in sympathectomized rabbit eyes. Exp. Eye Res. 34:1-6, 1982.
25. Ritch, R., Shields M.B., and Krupin T. Preface. In Falk, K.H. (Ed.) The glaucomas, St. Louis, MO: Mosby-Year Book Inc., 1996:xvii-xviii.
26. Bowd, C., Weinreb, R.N., Lee, B., et al. Optic disk topography after medical treatment to reduce intraocular pressure. Am. J. Ophthalmol. 130:280-286, 2000.
27. Sponsel, W.E., Dallas, N.L., and Burbridge, L. Visual field survival: The response to timolol therapy in open-angle glaucoma. Br. J. Ophthalmol. 67:220-227, 1983.
28. Epstein, D.L., Krug, J.H., Jr., Hertzmark, E., et al. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 96:1460-1467, 1989.
29. Kass, M.A., Gordon, M.O., Hoff, M.R., et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch. Ophthalmol. 107:1590-1598, 1989.
30. Schenker, H., Maloney, S., Liss, C., et al. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin. Ther. 21:-138-147, 1999.
31. Shedden, A., Laurence, J., and Tipping, R. Efficacy and tolerability of timolol maleate ophthalmic gelforming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: A six-month, double-masked, multicenter study. Clin. Ther. 23:440-450, 2001.